Rani TherapeuticsRANI
RANI
About: Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Employees: 106
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
32% more funds holding
Funds holding: 31 [Q3] → 41 (+10) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
8.72% less ownership
Funds ownership: 20.18% [Q3] → 11.46% (-8.72%) [Q4]
44% less call options, than puts
Call options by funds: $157K | Put options by funds: $279K
59% less capital invested
Capital invested by funds: $12.8M [Q3] → $5.23M (-$7.54M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
711%
upside
Avg. target
$9
711%
upside
High target
$9
711%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 58 / 188 met price target | 711%upside $9 | Buy Reiterated | 3 Apr 2025 |
Canaccord Genuity Edward Nash 65% 1-year accuracy 13 / 20 met price target | 711%upside $9 | Buy Maintained | 26 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 711%upside $9 | Buy Reiterated | 7 Feb 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
4 weeks ago
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Conference Call Participants Annabel Samimy - Stifel Eka Gigauri - Oppenheimer Julian Harrison - BTIG Mitchell Kapoor - H.C. Wainwright Chad Yahn - Maxim Group Xinwei An - Canaccord Genuity John Vandermosten - Zacks Operator Welcome to the Rani Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Neutral
GlobeNewsWire
4 weeks ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
Neutral
GlobeNewsWire
1 month ago
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
Neutral
GlobeNewsWire
1 month ago
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Neutral
GlobeNewsWire
6 months ago
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics' Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 333,333 shares of Common Stock, together with Series C common warrants to purchase up to an aggregate of 3,333,333 shares of Common Stock, in a registered direct offering. Each share of Common Stock (or pre-funded warrant) is being sold together with one Series C common warrant at a combined purchase price of $3.00. The Series C common warrants will have an exercise price of $3.00 per share and will expire 5 years from the date of issuance.
Neutral
GlobeNewsWire
6 months ago
Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2.
Neutral
GlobeNewsWire
7 months ago
Rani Therapeutics to Participate in September Investor Conferences
SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include:
Neutral
GlobeNewsWire
8 months ago
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity -
Neutral
GlobeNewsWire
9 months ago
Rani Therapeutics to Participate in August Investor Conferences
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include:
Neutral
GlobeNewsWire
9 months ago
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics' Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 446,753 shares of Common Stock, together with Series A common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock and Series B common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock, in a registered direct offering. Each share of Common Stock and pre-funded warrant is being sold together with one Series A common warrant to purchase one share of Common Stock and one Series B common warrant to purchase one share of Common Stock at a combined purchase price of $3.08. The Series A common warrants and Series B common warrants will each have an exercise price of $3.08 per share, will each be exercisable 6 months from the date of issuance, and, in the case of Series A common warrants, will expire 18 months from the date of issuance, and in the case of Series B warrants, will expire five and a half years from the date of issuance.
Charts implemented using Lightweight Charts™